| Literature DB >> 34504691 |
Tran Que Son1,2, Tran Hieu Hoc1, Nguyen Tien Quyet3, Tran Bình Giang4, Nguyen Ngoc Hung5, Tran Thanh Tung2, Tran Thu Huong6.
Abstract
INTRODUCTION: Minimally invasive pancreaticoduodenectomy is a technically complex technique, that is being used to treat periampullary malignancy. We provide our experience with laparoscopic-assisted pancreaticoduodenectomy (LAPD) with statistics on the outcomes of periampullary cancer patients. MATERIAL ANDEntities:
Keywords: Laparoscopic; Laparoscopic-assisted pancreatoduodenectomy; Periampullary tumours; Results; Whipple procedure
Year: 2021 PMID: 34504691 PMCID: PMC8417344 DOI: 10.1016/j.amsu.2021.102742
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Fig. 1The trocar positions.
Fig. 2The first phases of LAPD involve laparoscopic mobilization, organ dissection, lymph node transection. a, a tunnel was dissected posterior to the pancreatic neck and the pancreatic transection was made on the neck. b, completed pancreaticoduodenal dissection. c, two-layer duct-to-mucosa pancreaticojejunostomy using hand technique through abdominal wall incision with 5–8 cm length. D, pancreaticoduodenal mass (ampullary of Vater cancer – white arrow; pancreatic head – green arrow; duodenum – yellow arrow; lymph nodes – red arrow). IVC inferior vena cava, PV portal vein, CHA common hepatic artery, CBD common bile duct. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3Histopathology of the pancreaticoduodenal mass.
Clinical characteristics and preoperative outcomes for LAPD groups.
| Age, mean (SD) | 53.7 ± 9.5 |
|---|---|
| Sex, n (%) (Male/Female) | 17 (56.7)/13 (43.3) |
| ASA, n (%) (I, II) | 23 (76.7)/7 (23.3) |
| BMI, median (IQR), kg/m2 | 20.9 (19.7–22.4) |
| CA 19-9, median (IQR) | 101.1 (10.4–220.5) |
| Diabetes | 4 (13.3) |
| Hypertension | 2 (6.7) |
| Cardiovascular | 1 (3.3) |
| Chronic bronchitis | 1 (3.3) |
| ENBD or PTCD, n (%) | 5 (16.7) |
| Pancreatic duct width (≤3 mm), n (%) | 19 (63.3) |
| Jaundice | 26 (86.7) |
| Epigastric pain | 3 (10) |
| Severe haemorrage | 1 (3.3) |
| Pylorus-preserving PD | 9 (30) |
| Classical PD (cPD) | 21 (70) |
| Single-layer | 15 (50) |
| Two-layer (Blumgart's anastomosis) | 15 (50) |
| 15 (50) | |
| 12 (40) | |
| Continuous suture/Interupted suture | 26 (86.7)/4 (13.3) |
| Biliary drainage | 12 (40) |
| Anterior-mesocolic/posterior-mesocolic | 23 (76.7)/7 (23.3) |
| Continuous suture/interrupted suture | 20 (66.7)/10 (33.3) |
ASA American Society of Anaesthesiologists, BMI body mass index, CA 19-9 carbohydrate antigen 19-9, ENBD endoscopic nasal biliary drainage, PTCD percutaneous transhepatic cholangial drainage.
Reasons for conversion to open surgery.
| Reasons for conversion | Number of patients, n |
|---|---|
| Mesenteric jejunal artery bleeding | 1 |
| Superior mesenteric artery rupture | 1 |
| Gastroduodenal artery bleeding | 1 |
| Postoperative adhesion | 1 |
| Inflammatory intestinal adhesion post-acute pancreatitis | 1 |
| Inflammatory intestinal adhesion in tumour surrounding | 1 |
| 6 |
Intraoperative and postoperative data of the LAPD.
| OT, median (IQR), min | 277.5 (258.7–330) |
|---|---|
| EBL, median (IQR), mL | 319.5 (241.2–425) |
| Postoperative blood transfution, median (IQR), mL | 500 (0–787.5) |
| Postoperative LOS, median (IQR), days | 13 (12–18.2) |
| Albumin, median (IQR), bottles | 4 (3 - 7) |
| Aminoplasma, median (IQR), bottles | 11 (11 - 16) |
| Lipid, median (IQR), bottles | 8 (5.5–13.5) |
| Three Chamber Bags, median (IQR), bags | 7.5 (5 - 10) |
| Antibiotic, median (IQR), days | 12 (9 - 18) |
| Sandostatin, median (IQR), days | 8 (6 - 12) |
| Pain relief medication, median (IQR), days | 4 (3.75–6) |
| Oral intake, median (IQR), days | 5(5 - 6) |
| Withdraw abdominal drainage, median (IQR), days | 6 (5.75–7.25) |
| Withdraw biliary drainage, median (IQR), days | 30 (17.5–30) |
SD Standard Deviation; PD pancreaticoduodenectomy; OT operative time, EBL estimated blood loss, LOS length of hospital stays.
Short-term outcomes by operative method.
| Grade B/C POPF, n (%) | 4 (13.4) |
|---|---|
| DGE, n (%) | 2 (6.7) |
| Postpancreatectomy haemorrhage PPH, n (%) | 2 (6.7) |
| Abdominal bleeding | 1 (3.3) |
| Gastrojejunostomy anastomosis bleeding | 1 (3.3) |
| Biliary fistula, n (%) | 1 (3.3) |
| Postoperative intestinal obstruction, n (%) | 1 (3.3) |
| Overall morbidity, n (%) | 10* (33.4) |
| Number of patients with more than 1 complication, n (%) | 3 (10) |
| Clavien – Dindo, n (%), n (%) | |
| Grade I-II | 4 (13.4) |
| Grade ≥ III | 6 (20) |
| Re-operation, n (%) | 4 (13.3) |
| 30-Day mortality, n (%) | 3 (10) |
| Quality of life (QoL) | 26 (100) |
| Excellent | 19 (73.1) |
| Good | 3 (11.5) |
| Moderate | 2 (7.7) |
| Poor | 2 (7.7) |
DGE delayed gastric emptying, POPF postoperative pancreatic fistula, PPH postpancreatectomy haemorrhage.
Baseline characteristics of all pathologic results of the LAPD groups.
| Pathology, n (%) | |
|---|---|
| AoV cancer | 23 (76.7) |
| Pancreatic ductal adenocarcinoma | 2 (6.7) |
| Distal common bile duct cancer | 4 (13.3) |
| AoV NET (Grade 1) | 1 (3.3) |
| T2N0M0 | 12 (40) |
| T2N1M0 | 5 (16.7) |
| T3N0M0 | 6 (20) |
| T3N1M0 | 7 (23.3) |
| Well-differentiated | 1 (3.3) |
| Moderately differentiated | 26 (86.7) |
| Poorly differentiated | 3 (10) |
| Lesion major diameter, median (range), cm | 14.5 (12–16.5) |
| No. lymph nodes collected, median (IQR) | 15 (11 - 17) |
| Node positive, n (%) | 12 (40) |
| R0 resection, n (%) | 28 (93.3) |
Long-term survival in patients for periampullary of Vater manignancies
| Factors | Number of patient (n) | Survival time (months) | p | ||
|---|---|---|---|---|---|
| Mean | SD | 95% CI | |||
| LAPD patients | 30 | 29.9 | 3.2 | (23.6–36.4) | – |
| pT2 | 17 | 28.1 | 4.5 | (19.3–37.1) | 0.560 |
| pT3 | 13 | 24.2 | 3.0 | (18.3–30,1) | |
| pN0 | 18 | 36.8 | 3.5 | (29.9–43.7) | 0.012 |
| pN1 | 12 | 15.7 | 3.1 | (9.5–21.8) | |
| I–B staging | 12 | 36.9 | 4.2 | (28.6–45.2) | 0.042 |
| II–A staging | 6 | 26.5 | 4.5 | (17.6–35.3) | |
| II–B staging | 12 | 15.7 | 3.1 | (9.5–21.8) | |
Fig. 4Overall survival in patients with malignant disease. A, long-term survival for periampullary Vater malignancies; B, Overall survival according to tumour size; C, Overall survival according to lymph node metastases and D, overall survival followed to cancerous staging. p-value derived from the log-rank test.